美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · IONS近 30 天 17 則 · 第 1 / 1 頁
- Ionis Pharmaceuticals (IONS) Dropped, What Is Behind The Latest Attention?
- 阿斯特捷利康的廣泛產品線能否抵銷近期挫敗？Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
- Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
- Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
- Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
- PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
- Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
- Ionis Has Its First Neurology Launch, But Can Zanvastro Justify Its $285,000 Price?
- BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)
- Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
- Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
- Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
- How Novartis' Double-Stacked Failures Reverberated Through Biopharma
- Novartis Stock Tanks Following Third Major Pipeline Setback
- Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
- Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
- This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。